Valbenazine tosylate
- TRADE NAME: Ingrezza (Neurocrine Biosciences)
- INDICATIONS: Tardive dyskinesia
- CLASS: Vesicular monoamine transporter 2 inhibitor
- HALF-LIFE: 15–22 hours
- FDA APPROVAL DATE: 04/11/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Carbamazepine, Clarithromycin, Digoxin, Fluoxetine, Isocarboxazid, Itraconazole, Ketoconazole, MAO inhibitors, Paroxetine Hydrochloride, Phenelzine, Phenytoin, Quinidine, Rifampin, Selegiline, St John's Wort, Strong CYP2D6 inducers, Strong CYP3A4 inducers or inhibitors - PREGNANCY: May cause fetal harm
Please login to view the rest of this drug profile.
Page last updated 06/12/2024
